| Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial SS Shafti, B Shahveisi Journal of Clinical Psychopharmacology 30 (1), 44-47, 2010 | 50 | 2010 |
| Olanzapine vs. lithium in management of acute mania SS Shafti Journal of affective disorders 122 (3), 273-276, 2010 | 36 | 2010 |
| Aripiprazole versus quetiapine in treatment-resistant obsessive–compulsive disorder: a double-blind clinical trial S Shoja Shafti, H Kaviani Therapeutic advances in psychopharmacology 5 (1), 32-37, 2015 | 32 | 2015 |
| A comparative study between olanzapine and risperidone in the management of schizophrenia S Shoja Shafti, M Gilanipoor Schizophrenia research and treatment 2014, 2014 | 28 | 2014 |
| Amelioration of deficit syndrome of schizophrenia by norepinephrine reuptake inhibitor S Shoja Shafti, MS Jafarabad, R Azizi Therapeutic Advances in Psychopharmacology 5 (5), 263-270, 2015 | 25 | 2015 |
| Intractability of deficit syndrome of schizophrenia against adjunctive modafinil SS Shafti, S Akbari Journal of Clinical Psychopharmacology 36 (1), 45-49, 2016 | 16 | 2016 |
| Treatment-responsiveness of negative symptoms in schizophrenia: a double-blind placebo-control clinical trial SS SHOJA IRANIAN JOURNAL OF MEDICAL SCIENCES (IJMS) 31 (3), 135-138, 2006 | 15 | 2006 |
| Psychoanalysis in Persia SS Shafti American journal of psychotherapy 59 (4), 385-389, 2005 | 15 | 2005 |
| Quetiapine versus aripiprazole in the management of schizophrenia S Shoja Shafti, H Kaviani Therapeutic Advances in Psychopharmacology 5 (3), 166-171, 2015 | 14 | 2015 |
| Amelioration of negative symptoms in schizophrenia by escitalopram: A double-blind, placebo-controlled clinical trial S Shafti Clinical schizophrenia & related psychoses 1 (3), 255-258, 2007 | 12 | 2007 |
| Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial S Shoja Shafti, A Azizi Khoei Therapeutic Advances in Psychopharmacology 6 (5), 308-316, 2016 | 11 | 2016 |
| Odyssey of ‘negative symptoms’ of schizophrenia: rehabilitation vs stigmatization S Shoja Shafti Current Psychopharmacology 4 (1), 40-51, 2015 | 11 | 2015 |
| A comparative study on olanzapine and aripiprazole for symptom management in female patients with borderline personality disorder SS Shafti, H Kaviani Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 25 …, 2015 | 11 | 2015 |
| Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: A double-blind clinical trial. Therapeutic Advances in Psychopharmacology, 5 (1): 32-37 S Shoja Shafti, H Kaviani dx. doi. org/10.1177/2045125314560739, 2015 | 11 | 2015 |
| Comparison between lithium and valproate in the treatment of acute mania SS Shafti, B Shahveisi Journal of clinical psychopharmacology 28 (6), 718-720, 2008 | 11 | 2008 |
| Treatment of borderline personality disorder with olanzapine SS SHOJA Archives of Iranian medicine 9 (4), 403-405, 2006 | 11 | 2006 |
| Rehabilitation of schizophrenia: adjunctive therapy of negative symptoms S Shoja Shafti Iranian Rehabilitation Journal 2 (1), 15-25, 2004 | 11 | 2004 |
| Early psychiatric manifestation in a patient with primary progressive multiple sclerosis S SHAFTI, Z NIKNAM, P FALAH, L Zamani Archives of Iranian medicine 12 (6), 595-598, 2009 | 10 | 2009 |
| Drug--Specific Responsiveness of Negative Symptoms. SS Shafti, S Rey, A Abad International Journal of Psychosocial Rehabilitation 10 (1), 2005 | 10 | 2005 |
| EFFECTIVENESS OF BROMOCRIPTINE, FLUOXETINE AND NORTIPTYLINE IN AMELIORATING THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA SS SHOJA Archives of Rehabilitation (Journal of Rehabilitation) 5 (1617), 58-63, 2004 | 10 | 2004 |
